Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34722
Abstract: Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared with patients with the myeloproliferative phenotype. read more here.
Keywords: myelofibrosis response; response toxicity; ruxolitinib cytopenic; cytopenic myelofibrosis ... See more keywords
Cytopenic myelofibrosis: prevalence, relevance, and treatment
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2023.2203318
Abstract: ABSTRACT Introduction Cytopenic myelofibrosis is increasingly recognized as a phenotype of myelofibrosis presenting with low blood counts, lower driver mutation allele burden, increased likelihood of arising de novo, i.e. primary myelofibrosis, greater genomic complexity, worse… read more here.
Keywords: jak inhibitors; myelofibrosis prevalence; cytopenic myelofibrosis; myelofibrosis ... See more keywords